

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

**Sunday, 21 October 2018**

---

Satellites  
08:45 - 12:00

Estrasburgo

### **SA02, New Pieces to the HIV-1 Vaccine Puzzle: Germline Targeting Strategies and Immunization Protocols to Elicit Anti-HIV-1 bNAbs**

Hosted by: The Rockefeller University It is becoming evident that the design of a vaccine that elicits broadly protective antibodies against HIV-1 will require a meticulous engineering process to generate suitable germline targeting strategies that activate bNAb precursors and subsequently support antibody maturation in germinal centers. Encouraging results were obtained in a bNAb knock-in mouse model in which PGT121-like antibodies were elicited by step-wise immunization. Despite multiple efforts, these results have not been fully reproduced in wild type (wt) animal models with a polyclonal B cell repertoire. One of the hurdles to overcome in wt animals is the activation of bNAb precursors that are present in low frequencies. Recent studies have shown that high-affinity immunogens are necessary to efficiently activate and expand low-frequency bNAb precursors. An additional barrier for vaccine design in a wt system is the polyclonal nature of the antibody response. It is believed that immunogen refinement is necessary in order to focus the antibody response towards neutralizing epitopes and avoid distracting responses to non-neutralizing epitopes that could frustrate bNAb maturation by competition in the germinal centers. In this session, we will present progress achieved in the design of strategies to specifically activate and increase the frequency of bNAb precursors, as well as the results of immunization experiments aiming to elicit anti-HIV-1 bNAbs in wt animal models. 8:45 am Eliciting broadly neutralizing responses to the exposed N-terminal residues of the fusion peptide - Peter Kwong 9:00 am Discussion 9:05 am Induction of glycan-reactive bNAb B cell lineages - Kevin Saunders 9:20 am Discussion 9:25 am Sequential immunization strategies to elicit bNAbs in animal models with a polyclonal B cell repertoire - Amelia Escolano 9:40 am Discussion 9:45 am Design of germline targeting immunogens to elicit antibodies targeting the CD4-binding site and V3-N332 epitopes on Env - Harry Gristick 10:00 am Discussion 10:05 am Dissecting neutralizing antibodies to guide rational HIV vaccine design - Marit van Gils 10:20 am Discussion 10:25 am Nanoparticle-display of native-like envelope trimers - Kwinten Sliepen 10:40 am Discussion 10:45 am Anti-idiotypic antibodies as a strategy to prime bNAb precursors - Andrew McGuire 11:00 am Discussion 11:05 pm Structural basis for germline VRC01 antibody recognition of a glycosylated HIV-1 envelope CD4-binding site - Marie Pancera 11:20 am Discussion 11:25 am HIV-1 MPER Germline Targeting - Torben Schiffner 11:40 am Discussion 11:45 am Sequential Immunization with Different Repaired and Stabilized HIV-1 Envelope Trimers Induces broad Tier2 neutralization in Rabbits - Johannes P.M. Langedijk 11:55 pm Discussion

#### **Chairs:**

Amelia Escolano (The Rockefeller University, United States)  
Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)

Satellites  
09:00 - 17:00

Dresden & Stuttgart

### **SA01, Advocates' Pre-Conference Workshop**

Hosted by: IRMA, AVAC and others This full day pre-conference workshop will provide an overview of the field and amplify certain topics to contextualize the themes and issues that will be presented at HIVR4P; will connect research and advocacy priorities and explore common goals; and build the capacity of advocates and trial staff to better engage with emerging issues in the field. This workshop is especially designed for advocates, scholarship recipients, new investigators, first time attendees, community liaison officers at trials and other interested stakeholders to what HIVR4P.

#### **Chairs:**

Jim Pickett (AIDS Foundation of Chicago, United States)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Satellites  
12:30 - 15:30

Estrasburgo

### SA03, Progress in Inducing HIV Broad Neutralizing Antibodies

Hosted by: The Scripps Research Institute and Duke University This session will explore the progress made in inducing HIV broad neutralizing antibodies. 12:30 pm Overview of the bnAb Problem- Barton Haynes 12:40 pm V2 apex as a target - Raiees Andrabi 12:55 pm Discussion 1:00 pm Polyclonal Ab response mapping by EM - Andrew Ward 1:15 pm Discussion 1:20 pm Mouse models of bnAb germ line targeting immunogens - Facundo Batista 1:35 pm Discussion 1:40 pm Host control of bnAbs - Todd Bradley 1:55 pm Discussion 2:00 pm Overcoming roadblocks of improbable mutations in bnAb B cell lineages - Kevin Wiehe 2:15 pm Discussion 2:20 pm The impact of antibody isotype on neutralization - Penny Moore 2:35 pm Discussion 2:40pm Structural Diversity of antibody recognition at the V3-glycan epitope - Priyamvada Acharya 2:55 pm Discussion 3:00 pm SHIV infected Rhesus macaques as a model for bnAb development - George Shaw 3:15 pm Discussion 3:20 pm BnAbs - The way forward- Dennis Burton

#### Chairs:

Dennis Burton (The Scripps Research Institute, United States)  
Barton Haynes (Duke University, United States)

Satellites  
12:30 - 14:30

Marsella

### SA06, Social Sciences in Vaccine Trials: A Booster to Recruit Volunteers

Hosted by: ANRS and Vaccine Research Institute The recruitment of healthy, HIV-seronegative patients to HIV preventive vaccine trials has fluctuated since the early days of their implementation. There are numerous reasons for this, including the normalization of the epidemic, the displacement of HIV community action towards other causes, the transformation of disease management, and the lack of direct benefits. Vaccination is being increasingly rejected. At a time when scientific advances offer hope for the development of preventive HIV vaccine strategies, the recruitment of volunteers to future clinical trials may well become a stumbling block. This symposium aims to highlight the contribution that social science research has made to this complex process by both addressing the particular nature of HIV infection and placing the topic in a more global context of recruitment to preventive vaccine trials. 15 minutes Welcome  
5 minutes François Dabis, Director of the ANRS, France Yves Lévy, Director of VRI and CEO of Inserm, France  
15 minutes Recruitment of healthy volunteers for HIV vaccine trials: a stumbling block?  
Jean-Daniel Lelièvre, Vaccine Research Institute, France  
15 minutes Volunteers/Participants Recruitment/Enrolment in Africa  
Morenike Folayan, Obafemi Awolowo University, Nigeria  
15 minutes Exceptional Risk: US Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.  
Marci Cottingham, University of North Caroline, USA  
15 minutes Key Populations Enrolment  
Peter Newman, University of Toronto, Canada  
15 minutes Participant Recruitment in an Outbreak Context: The Ebola vaccine trials in Sierra Leone  
Luisa Enria, University of Bath, UK  
40 minutes General discussion and Round Table:  
What Kind of Social Science Research to support Clinicians Issues?  
Giulio Maria Corbelli, ECAB/EATG, Italy  
Frédéric Le Marcis, ENS Lyon, France  
Warren Mitchell, AVAC, USA  
Caroline Ollivier-Yaniv, Université Paris-Est Créteil, France  
10 minutes Conclusion  
Guillaume Lachenal and Jean-Daniel Lelièvre  
A snack will be served to all the participants after the Symposium from 14:30 to 15:00

#### Chairs:

Guillaume Lachenal (Université Paris-Diderot, France)  
Jean-Daniel Lelièvre (Vaccine Research Institute/VRI, Hôpital Henri Mondor, France)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Satellites  
14:00 - 17:00

Burdeos

### SA05, Planning for Success: Next Steps for Dapivirine Ring

Hosted by: OPTIONS and IPM Researchers, implementers, advocates, policy makers and dapivirine ring users will share research and experience to refine and coalesce on practical next steps for introduction.

#### Chairs:

Elizabeth Gardiner (AVAC, United States)  
Nadia Sutton (Johnson & Johnson, Global Public Health, United States)

Satellites  
15:00 - 18:00

Marsella

### SA07, Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention

Hosted by: International AIDS Vaccine Initiative (IAVI) and the US Military HIV Research Program (MHRP) The purpose of this meeting is to convene researchers and other stakeholders to discuss how African MSM can be successfully engaged in planned HIV biomedical prevention trials, discuss various recruitment and retention strategies from Africa and develop best practices and tools to inform future research in Africa and other regions.

- Overview: HIV Prevalence, HIV Incidence, and Retention from Key African Studies of MSM – Joshua Kimani, University of Manitoba Kenya office •Plenary: Including African MSM in HIV biomedical prevention research – opportunities, challenges – Anatoli Kamali, IAVI •Lessons learned in recruitment and retention of African MSM
- Frederick Otieno, Nyanza Reproductive Health Society •Elizabeth Wahome, KEMRI •Zahra Parker, Research Manager, U.S. Military HIV Research Program-Nigeria •Hannah Kibuuka, Research Physician, Makerere University Walter Reed Project •Victor Akelo, KEMRI/CDC Senior Research Officer, Kisumu, Kenya •Travis Sanchez, Emory University
- Strategic community engagement
- Sylvia Adebajo, Population Council, Nigeria •Jeffrey Walimbwa, ISHTAR, Kenya
- Moderated Panel Q & A Discussion •Closing remarks – Merlin Robb, U.S. Military HIV Research Program

#### Chairs:

Kenneth H. Mayer (Fenway Health, United States)  
Sylvia Adebajo (Population Council, Nigeria)

Satellites  
16:00 - 18:00

Estrasburgo

### SA04, State of the Art of HIV bNAbs for Prevention of HIV Infection

Hosted by: HIV Vaccine Trials Network and HIV Prevention Trials Network This session will cover current topics on the clinical development of broadly active neutralizing antibodies to HIV.

#### Chairs:

Larry Corey (Fred Hutchinson Cancer Research Center, United States)  
Myron Cohen (University of North Carolina, United States)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## **Download Program (PDF)**

**Monday, 22 October 2018**

---

Satellites  
08:30 - 11:30

Bristol

### **SA16, Current State of Play: PrEP Implementation Update and Challenges**

Hosted by: ICAP at Columbia University, World Health Organization (WHO), AVAC, CHAI and HIV Prevention Trials Network (HPTN) This session will provide participants with an update on where we are with PrEP and future products, current understanding of the different approaches to oral PrEP implementation in low- and middle-income countries, the challenges faced and solutions found in efforts to scale-up programs. Panel discussions will elicit the perspectives from key experts and include debate on current controversies when considering and prioritizing PrEP implementation.

**Chairs:**

Wafaa El-Sadr (Mailman School of Public Health, Columbia University, United States)  
Rachel Baggeley (World Health Organization, Switzerland)

Satellites  
08:30 - 11:30

Oxford

### **SA18, A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities with the HIV Vaccine Trials Network (HVTN)**

Hosted by: HIV Vaccine Trials Network (HVTN) The HVTN has conducted more than 75 clinical trials across four continents, evaluating the safety, tolerability and immunogenicity of numerous study products, delivery methods and regimens. During the conducting of all HVTN studies, participant data and specimens are collected at multiple time points to evaluate immunogenicity and generate data across several cellular and humoral research platforms. In addition, extra samples are collected and stored for use in other studies potentially related to vaccinology, immunology and HIV. The HVTN maintains comprehensive metadata for all specimens, and has collected more than one million pages of case report form data from study participants to date. The HVTN is committed to making the specimens and data collected in HVTN studies available to investigators around the world to foster the development of diverse, hypothesis-driven research projects to advance HIV vaccine science. This session will provide a brief overview of the types of specimens, data and resources available to investigators to formulate research hypotheses, as well as steps to approach collaborating with the HVTN. This overview will be followed by a showcase of several, ongoing research projects initiated by investigators in collaboration with the HVTN and utilizing HVTN specimens and/or data.

**Chairs:**

James Kublin (Fred Hutchinson Cancer Research Center, United States)  
Ashley Clayton

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## **Download Program (PDF)**

Satellites  
08:30 - 11:30

Dresden & Stuttgart

### **SA08, Catalyzing Translational Research to Advance HIV Vaccine and Immune-based Cure Research in Africa: Cross-cutting Translational Research and Capacity Strengthening in Africa**

Hosted by: IAVI and University of KwaZulu Natal This satellite will showcase early and mid-level career African scientists supported by a 15-year IAVI-led USAID-funded capacity program and from the SANthe consortium, part of the DELTAS Africa Initiative, an independent funding scheme of the African Academy of Sciences' (AAS's) Alliance for Accelerating Excellence in Science in Africa (AESA). This satellite workshop will aim to provide evidence of the impact that these investments have created in translational biomedical research in Africa. This session will also host a moderated panel discussion by African investigators to share personal career pathways, experiences and perspectives on how research capacity and research outputs could be further strengthened and improved on the continent.

#### **Chairs:**

Daniel Ochiel (IAVI, Kenya)  
Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)

Satellites  
08:30 - 11:30

Estrasburgo

### **SA10, Immunological Mechanisms of Inducing HIV Immunity in Infants**

Hosted by: Division of AIDS, NIAID, NIH The session aims to better understand: (i) how the unique tolerogenic nature of the human fetal immune system and developing immune-tolerance in infants provide a unique setting for B-cell maturation pathways and development of early and broad immunity to HIV; and (ii) how to prioritize HIV candidate vaccines and target populations for assessment of infant HIV immunization.

#### **Chairs:**

Mary Marovich (Division of AIDS, NIAID, NIH, United States)  
Sallie Permar (Duke University Medical Center)  
Anjali Singh (Division of AIDS, NIAID, NIH)

Satellites  
08:30 - 11:30

Burdeos

### **SA12, Voices in the Long-acting PrEP Movement: Fostering Dialog Between End-users and Product Developers During the Product Development Process**

Hosted by: RTI International, Desmond Tutu HIV Research Foundation, AVAC and IAVI This satellite session aims to demonstrate and discuss strategies to foster open and iterative dialog between end-users and product developers of long-acting HIV prevention products. The objective of hosting this satellite is directly in line with the theme of this year's HIVR4P Conference, From Research to Impact. Satellite presenters, those working both in product development and those interfacing with target populations of young women in Southern Africa, aim to achieve synergistic solutions for the development of long-acting HIV PrEP products that are safe, effective, acceptable and appropriate for their target end-users, a goal that will ultimately achieve the greatest public health impact.

#### **Chairs:**

Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## **Download Program (PDF)**

Satellites  
08:30 - 11:30

Marsella

### **SA14, GPP@10 -- Setting New Standards for Clinical Trial Engagement Globally**

Hosted by: AVAC, Amsterdam Institute for Global Health and Infectious Diseases Through presentations and moderated discussions, the session will articulate evolved the Good Participatory Practices (GPP) after 10 years of implementation, debate challenges and questions around GPP, and explore consensus on GPP as a standard in clinical trials.

#### **Chairs:**

Stacey Hannah (AVAC, United States)  
Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)

Satellites  
12:00 - 15:00

Bristol

### **SA17, Love, Power and PrEP: Addressing Relationship Dynamics and Intimate Partner Violence to Promote Successful HIV Prevention for Women and Girls**

Hosted by: FHI 360, RTI International, Population Council and Wits Reproductive Health and HIV Institute To successfully empower women and girls to protect themselves against HIV, researchers, policy makers, funders, advocates and programmers need a nuanced understanding of how relationship dynamics affect HIV prevention and interventions that jointly address these issues. This satellite session will summarize the state of the evidence on the effect of gender inequality on the HIV risk of women and girls and their use of HIV prevention methods, including pre-exposure prophylaxis (PrEP). New evidence will be presented from adolescent girls, young women, key populations and male partners in Kenya, Ghana and Tanzania on their HIV prevention needs and preferences, including their views on PrEP and how intimate partner violence (IPV) could affect PrEP access and use. A panel of experts will present new evidence from clinic- and community-based interventions (CHARISMA, EMPOWER and Project SOAR) implemented in South Africa and Tanzania, jointly addressing relationship dynamics, IPV, HIV prevention and PrEP.

#### **Chairs:**

Kawango Agot (Impact Research & Development Organization, Kenya)  
Jared Baeten (University of Washington, United States)

Satellites  
12:00 - 15:00

Oxford

### **SA19, Whose Desire? Whose Choice? A Debate on the Future of HIV Prevention**

Hosted by: AVAC and IRMA Lively, moderated discussion and debate featuring speakers from funding agencies, research networks and sites, product developers and the advocacy community. Panelists will unpack the evolving HIV prevention research priorities and product development agendas, and share thoughts on what is necessary to develop prevention products that people desire and what we mean by giving people "choices."

#### **Chairs:**

Mitchell Warren (AVAC, United States)  
Helen Rees (Wits Reproductive Health and HIV Institute, South Africa)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## **Download Program (PDF)**

Satellites  
12:00 - 15:00

Dresden & Stuttgart

### **SA09, Fc-mediated Antibody Functions Impacting HIV Prevention**

Hosted by: NIH/NIAID/Division of AIDS Fc-mediated antibody functions, including antibody-dependent cell cytotoxicity (ADCC), are potential mechanisms that the immune system can resource to prevent the establishment of HIV infection by eliminating HIV and/or HIV-infected cells. This session will bring together investigators to review NHP and clinical data on Fc-mediated antibody functions in the context of HIV/SIV infection and vaccine design, to discuss the biological relevance and limitations of different assays and to provide insights into immunogen design strategies to maximize the induction of antibodies with Fc-mediated functions that could impact HIV infection and persistence.

#### **Chairs:**

Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)  
Stephen Kent (University of Melbourne, Australia)

Satellites  
12:00 - 15:00

Estrasburgo

### **SA11, Accelerating a Labor of Love: Time to Transform HIV Prevention for Pregnant and Breastfeeding Women**

Hosted by: Jhpiego, MTN, PHASES, AVAC A growing body evidence supports the need to expand biomedical HIV prevention options during pregnancy and breastfeeding, periods known to have increased risk for HIV acquisition for both women and their infants. While the large majority of biomedical HIV prevention trials have excluded pregnant and breastfeeding women, this trend is starting to change. HIV pre-exposure prophylaxis (PrEP) programs are starting to serve pregnant and breastfeeding women, and the conversation around equitable access for these populations is evolving. The proposed session would highlight the growing body of evidence, action, advocacy, and ethics around increasing access for pregnant and breastfeeding women to safe and effective biomedical HIV prevention options.

#### **Chairs:**

Sharon Hillier (University of Pittsburgh, United States)  
Kelly Curran

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Satellites  
12:00 - 15:00

Burdeos

### **SA13, It Only Hurts a Little: Long-acting Injectables for HIV Prevention and Treatment**

Hosted by: Center for HIV Identification, Prevention and Treatment Services at the University of California, Los Angeles Ongoing clinical trials of long-acting injectable antiretroviral medications are being studied currently as both HIV prevention and maintenance of virologic suppression in HIV treatment. If safe and effective, long-acting agents have the potential to significantly impact the HIV epidemic by eliminating the requirement for daily oral dosing of antiretrovirals. This may have significant benefits for individuals living with or at risk for HIV, particularly among those who also have co-morbidities that complicate daily routinization of medication dosing, such as mental health and substance use disorders. Such individuals also commonly face structural issues, including housing instability and food insecurity, which can interfere with their capacity for daily oral medication adherence and persistence. With the first regulatory approvals of long-acting injectable antiretrovirals imminent, this interactive satellite session aims to facilitate efforts to mobilize, prepare and plan for culturally responsive, equitable and sustainable scale-up of long-acting injectable prevention and treatment agents for key populations in high-, middle- and low-income countries. The session will engage multidisciplinary stakeholders, including academic experts, policy researchers and civic society members, in a dialogue to articulate the challenges for implementation and uptake and, in particular, how acceptability and/or barriers may differ from those applicable to daily oral tablet formulations. The session will convene two moderated panels to discuss clinical, behavioral, policy and community considerations associated with the implementation of long-acting injectable antiretrovirals for prevention and treatment in the context of different international resource settings and key populations (for example, MSM, transgender women, pregnant and parenting cisgender women, youth).

#### **Chairs:**

Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)  
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)

Satellites  
12:00 - 15:00

Marsella

### **SA15, Human Centric Vaccine Discovery**

Hosted by: EAVI2020 This session will highlight the importance of discovery-phase clinical vaccine trials.

#### **Chairs:**

Robin Shattock (Imperial College, United Kingdom)

Opening Plenary  
16:00 - 18:00

Auditorium

### **PL01, Planning for Success (and the Challenges Ahead)**

Plenary 1 opens HIVR4P 2018 with a broad statement of our goals, a look at the major challenges facing the field as we convene and a tribute to some of the researchers and advocates who are taking it forward and keeping us focused.

#### **Chairs:**

Jose Alcamí (Instituto de Salud Carlos III, Spain)  
Susan Buchbinder (San Francisco Department of Public Health, United States)  
Mike Chirenje (University of Zimbabwe, Zimbabwe)  
Georgia Tomaras (Duke University, United States)

**Welcome to HIVR4P 2018**

**16:00 - 16:10**

Jose Alcamí (Instituto de Salud Carlos III, Spain)



HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

<b>Desmond Tutu Award for HIV Prevention and Human Rights</b> Georgia Tomaras (Duke University, United States)	<b>16:10 - 16:17</b>
<b>HIV Vaccines: Where Are We and What Next?</b> Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)	<b>16:17 - 16:47</b>
<b>Novel Trial Designs for a Complex Environment</b> Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)	<b>16:47 - 17:17</b>
<b>Ending the HIV/AIDS Pandemic: The Critical Role of HIV Prevention Science</b> Anthony Fauci (National Institute of Allergy and Infectious Diseases, NIH, United States)	<b>17:17 - 17:47</b>
<b>The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy</b> Manju Chatani-Gada (AVAC, United States)	<b>17:47 - 17:55</b>
<b>HIVR4P 2018 Scholars</b> Mike Chirenje (University of Zimbabwe, Zimbabwe)	<b>17:55 - 18:00</b>

Welcome Reception  
18:00 - 20:00

Foyer

## Welcome Reception

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

**Tuesday, 23 October 2018**

---

Plenary  
08:30 - 10:00

Auditorium

### **PL02, What Happens First: Understanding Susceptibility, Transmission and Early Infection**

Plenary 2 dives deep into some of the most fundamental and challenging questions about the earliest moments of infection, when HIV enters the complex mucosal microenvironment, and how untangling the mysteries of susceptibility and infection can lead to smarter, more targeted prevention approaches.

#### **Chairs:**

Felipe Garcia (IDIBAPS, Spain)

Julie McElrath (Fred Hutchinson Cancer Research Center, United States)

#### **Visualizing HIV Transmission and Prevention**

**08:30 - 09:00**

Thomas Hope (Northwestern University, United States)

#### **First Responders: What Early Infection Teaches About Prevention and Functional Cure Strategies**

**09:00 - 09:30**

Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)

#### **Untangling Hormonal Impacts on the Vaginal Microbiome and HIV Acquisition Risk**

**09:30 - 10:00**

Sharon Achilles (University of Pittsburgh, United States)

Oral  
10:30 - 12:00

Londres

### **OA01, Location, Location, Location: Mucosal Mediators of Risk**

#### **Chairs:**

Doug Kwon (Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital and Harvard Medical School, United States)

Lindi Masson (University of Cape Town, South Africa)

Oral  
10:30 - 12:00

Bristol

### **OA02, Immunity in Human Vaccine Trials**

#### **Chairs:**

Laura Richert (Vaccine Research Institute/VRI, France)

Gabriella Scarlatti (San Raffaele Scientific Institute, Italy)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Oral  
10:30 - 12:00

Oxford

### OA03, Structure and Maturation of bNAbs

#### Chairs:

Alejandro Balazs (Ragon Institute of MGH, MIT and Harvard, United States)

Oral  
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

### OA04, Entry Into the PrEP Continuum

#### Chairs:

Sybil Hosek (Stroger Hospital of Cook County, United States)  
Rupa Patel (Washington University in St. Louis, United States)

Meet the Experts Lunch  
12:00 - 13:00

Toulouse & Lyon

### ME01, Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges, and HIV-affected communities.

#### Chairs:

Sharon Achilles (University of Pittsburgh, United States)  
Eric Arts (University of Western Ontario, Canada)  
Emily Bass (AVAC, United States)  
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)  
Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)  
Zhiwei Chen (The University of Hong Kong AIDS Institute, China)  
Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States)  
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)  
Andrew Harman (The Westmead Institute, University of Sydney, Australia)  
Walid Heneine (CDC, United States)  
Thomas Hope (Northwestern University, United States)  
Luciana Kamel (Fiocruz, Brazil)  
Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)  
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)  
Irene Mukui (National AIDS & STI Control Program, Kenya)  
Jeffrey Murray (FDA, United States)  
Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)  
Manish Sagar (Boston University, United States)  
Kevin Saunders (Duke Human Vaccine Institute, United States)  
William Schief (The Scripps Research Institute and IAVI, United States)  
Alexandra Schuetz (MHRP Thailand, Thailand)  
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)  
Eloisa Yuste (Instituto de Salud Carlos III, Spain)

**Meet the Experts Lunch**

**12:00 - 13:00**

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Oral  
13:00 - 14:30

Londres

### **OA05, If I Choose, Will I Use? Products, People and Preferences**

#### **Chairs:**

Mary Aikenhead (Bill and Melinda Gates Foundation, United States)  
Mina Hosseinipour (University of North Carolina at Chapel Hill, Malawi)

Oral  
13:00 - 14:30

Bristol

### **OA06, Mucosal Models of Prevention**

#### **Chairs:**

Carolina Herrera (Imperial College London, United Kingdom)  
Thandi Onami (Bill & Melinda Gates Foundation, United States)

Oral  
13:00 - 14:30

Oxford

### **OA07, Understanding Protection Against HIV From the T Cell Perspective**

#### **Chairs:**

Marcus Altfeld (Heinrich Pette Institute, Germany)  
Richard Koup (Vaccine Research Center, United States)

Oral  
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

### **OA08, bNAbs for Prevention**

#### **Chairs:**

Boris Juelg (Ragon Institute of MGH, MIT and Harvard, United States)  
Alexandra Trkola (University of Zurich, Switzerland)

Symposium  
15:00 - 16:30

Londres

### **SY01, We Want bNAbs: Passively Infused and Induced by Vaccines**

This session will look at state-of-the-art passive infusion designs, including optimal combinations to achieve maximum breadth, coverage, potency and durability. In addition, multiple vaccine concepts designed to induce bNAbs will be presented, from the stage of basic concept up to the clinical trials pipeline.

#### **Chairs:**

Marina Caskey (The Rockefeller University, United States)  
Quentin Sattentau (Sir William Dunn School of Pathology, United Kingdom)

#### **Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy**

**15:00 - 15:18**

Zhiwei Chen (The University of Hong Kong AIDS Institute, China)

## Download Program (PDF)

<b>Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It's Working?</b>	<b>15:18 - 15:36</b>
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)	
<b>Generation of Immunogens Based on HIV-1 Envelopes From Patients With Broadly Neutralizing Responses Within the First 6 Months of Infection</b>	<b>15:36 - 15:54</b>
Eloisa Yuste (Instituto de Salud Carlos III, Spain)	
<b>HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing Antibodies</b>	<b>15:54 - 16:12</b>
Kevin Saunders (Duke Human Vaccine Institute, United States)	
<b>Progress in Germline-targeting Vaccine Design for HIV</b>	<b>16:12 - 16:30</b>
William Schief (The Scripps Research Institute and IAVI, United States)	

Symposium  
15:00 - 16:30

Bristol

## SY02, Early Invaders: Establishment of HIV Infection

This session addresses virus-host interaction at the mucosal border where transmission occurs and where cells involved in early immune responses are both viral targets and defense mechanisms.

### Chairs:

Cecilia Cabrera (IrsiCaixa AIDS Research Institute, Spain)  
Penny Moore (University of the Witwatersrand, South Africa)

<b>Selection of Transmitted Founder Viruses During Sexual HIV-1 Acquisition</b>	<b>15:00 - 15:22</b>
Manish Sagar (Boston University, United States)	
<b>Identification of a New HIV Transmitting Target Cell in Human Genital Tissue</b>	<b>15:22 - 15:44</b>
Andrew Harman (The Westmead Institute, University of Sydney, Australia)	
<b>Characteristics Leading to HIV Trapping in the Female Genital Tract and Systemic Primary Infection During Transmission</b>	<b>15:44 - 16:06</b>
Eric Arts (University of Western Ontario, Canada)	
<b>Mucosal Immunology in the Context of Acute HIV Infection and HIV Remission Studies</b>	<b>16:06 - 16:28</b>
Alexandra Schuetz (MHRP Thailand, Thailand)	

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Symposium  
15:00 - 16:30

Oxford

### **SY03, Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials**

This session will explore challenges in designing and conducting the next generation of HIV prevention trials. Topics discussed will include regulatory perspectives, novel trial designs, ethical considerations in provision of standard of prevention, and active community engagement in the design and successful implementation of complex trials in an era of proven HIV prevention tools (including voluntary medical male circumcision and oral PrEP).

#### **Chairs:**

Peter Godfrey-Faussett (UNAIDS, Switzerland)

Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)

<b>Regulatory Perspectives for Streamlining HIV Prevention Trials</b> Jeffrey Murray (FDA, United States)	<b>15:00 - 15:22</b>
<b>Novel Trial Design in the Era of Successful HIV Prevention Interventions</b> Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)	<b>15:22 - 15:44</b>
<b>The Landscape is Changing... [It's] Quite a Complicated Issue" : Perspectives on the Standard of Prevention in South African HIV Vaccine Trials</b> Zaynab Essack (Human Sciences Research Council, South Africa)	<b>15:44 - 16:06</b>
<b>Strengthen Community Expertise on the Important Aspects of Clinical Trial Design</b> Luciana Kamel (Fiocruz, Brazil) Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)	<b>16:06 - 16:28</b>

Symposium  
15:00 - 16:30

Marsella, Burdeos & Estrasburgo

### **SY04, ARVs for Prevention: Extrapolating from Data to Clinical Practice**

Data on mechanisms for PrEP efficacy are somewhat limited, and interpretation varies in creating policy about timing of starting and stopping PrEP for protection. This session will explore the PK, PD and clinical trials, and discuss implications of what is currently known for developing policy on PrEP.

#### **Chairs:**

Lara Coelho (Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Brazil)

Clemensia Nakabiito (MUJHU Research Collaboration, Uganda)

<b>Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last?</b> Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)	<b>15:00 - 15:22</b>
<b>Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics and Pharmacodynamics of ARVs for PrEP</b> Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States)	<b>15:22 - 15:44</b>
<b>Understanding PrEP Effectiveness in Different Populations in the Context of Public Health Programs</b> Irene Mukui (National AIDS & STI Control Program, Kenya)	<b>15:44 - 16:06</b>

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

### **The PrEP Paradigm for Prevention, Advocacy and Implementation in sub-Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of Data**

**16:06 - 16:28**

Emily Bass (AVAC, United States)

Poster Discussion  
16:45 - 17:30

Londres

### **PD01, Revealing Targets for Prevention and Cure**

#### **Chairs:**

Damian Purcell (Doherty Institute, University of Melbourne, Australia)  
Jesus Salazar-Gonzalez (Mrc/uvri And Lshmt Uganda Research Unit, Uganda)

Poster Discussion  
16:45 - 17:30

Bristol

### **PD02, MEN-ding the Gaps**

#### **Chairs:**

Kennedy Mupeli (Center for Youth of Hope (CEYOHO), Botswana)  
Michelle Rodolph (WHO, Switzerland)

Poster Discussion  
16:45 - 17:30

Oxford

### **PD03, Insights From Vaccines for Improved Breadth, Potency and Durability**

#### **Chairs:**

Anatoli Kamali (International AIDS Vaccine Initiative, Kenya)  
Hanneke Schuitemaker (Janssen Vaccine and Prevention, Netherlands)

Poster Discussion  
16:45 - 17:30

Marsella, Burdeos & Estrasburgo

### **PD04, PrEP: Doing It Right at Delivery**

#### **Chairs:**

Joshua Kimani (University of Nairobi, Kenya)  
Benny Kottiri (USAID, United States)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## **Download Program (PDF)**

Poster Discussion  
16:45 - 17:30

Dresden & Stuttgart

### **PD05, Microbiome: When Microorganisms and the Immune System Meet**

**Chairs:**

Sinaye Ngcapu (Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa)  
Sergio Serrano-Villar (Hospital Universitario Ramón y Cajal, Spain)

Poster  
17:30 - 19:30

Poster Hall

### **Poster Session 01**

Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 23 October. Even-numbered abstracts will be presented in Poster Session 02 on Wednesday, 24 October.



HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

**Wednesday, 24 October 2018**

---

Plenary  
08:30 - 10:00

Auditorium

### **PL03, The Future is Now: Next Steps in Developing New Prevention Options**

Plenary 3 answers the question, "What's new in prevention?" with a look at systemic and topical agents in development, new approaches to vaccines and new methods of delivery that could transform the future of HIV prevention.

#### **Chairs:**

Julia del Amo (Instituto de Salud Carlos III, Spain)  
Ian McGowan (Orion Biotechnology, Spain)

**Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis** **08:30 - 09:00**

Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)

**On-demand Topical Agents for HIV Pre-exposure Prophylaxis** **09:00 - 09:30**

Craig Hendrix (Johns Hopkins University, United States)

**Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce Neutralizing Antibodies** **09:30 - 10:00**

Rogier Sanders (Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands)

Oral  
10:30 - 12:00

Londres

### **OA09, Translating Immunity From Pre-clinical Animal Models to Humans**

#### **Chairs:**

Mariangela Cavarelli (CEA, France)  
Roger LeGrand (CEA, France)

Oral  
10:30 - 12:00

Bristol

### **OA10, Key to the Response: Populations, Partners and Prevention**

#### **Chairs:**

Kenneth H. Mayer (Fenway Health, United States)  
Valdilea Veloso (Fundação Oswaldo Cruz, Brazil)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Oral  
10:30 - 12:00

Oxford

### OA11, Novel Vaccine Strategies

#### Chairs:

Yoann Aldon (Imperial College London, United Kingdom)  
Susan Barnett (Bill and Melinda Gates Foundation, United States)

Symposium  
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

### SY11, ARVs for Prevention in Women of Childbearing Age

#### Chairs:

Elizabeth Bukusi (KEMRI, Kenya)  
Gita Ramjee (South African Medical Research Council, South Africa)

<b>No Woman Left Behind: An Ethical Framework for Prevention Studies in Reproductive Age Women</b>	<b>10:30 - 10:52</b>
Annie Lyerly (University of North Carolina, United States)	
<b>Efavirenz and Dolutegravir: A Tale of Two ARVs</b>	<b>10:52 - 11:14</b>
Elaine Abrams (Columbia University, United States)	
<b>Studying Periconception Outcomes in Women on ARVs in Brazil</b>	<b>11:14 - 11:36</b>
Adele Benzaken (Ministry of Health, Brazil, Brazil)	
<b>Striking a Balance</b>	<b>11:36 - 11:58</b>
Sharon Hillier (University of Pittsburgh, United States)	

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Meet the Experts Lunch  
12:00 - 13:00

Toulouse & Lyon

### ME02, Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges, and HIV-affected communities.

#### Chairs:

Elaine Abrams (Columbia University, United States)  
Rama Amara (Emory University, United States)  
Adele Benzaken (Ministry of Health, Brazil, Brazil)  
Martha Brady (PATH, United States)  
Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South Africa)  
Mary Carrington (Frederick National Laboratory for Cancer Research, United States)  
Alex Coutinho (Partners in Health, Rwanda)  
Anthony Cunningham (The Westmead Institute, The University of Sydney, Australia)  
Maria del Rosario Leon (Impacta Salud y Educacion, Peru)  
Sarit Golub (Hunter College, United States)  
Renee Heffron (University of Washington, United States)  
Craig Hendrix (Johns Hopkins University, United States)  
Sharon Hillier (University of Pittsburgh, United States)  
Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)  
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)  
Annie Lyerly (University of North Carolina, United States)  
Maximilian Muenchhoff (Pettenkofer-Institute, Germany)  
Zaza Ndhlovu (University of KwaZulu Natal, South Africa)  
Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)  
R. Keith Reeves (Beth Israel Harvard, United States)  
Rogier Sanders (Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands)  
Hasina Subedar (Department of Health, South Africa)

**Meet the Experts Lunch**

**12:00 - 13:00**

Oral  
13:00 - 14:30

Londres

### OA12, Contraception and HIV Risk: Still Between a Rock and a Hard Place

#### Chairs:

Maureen Goodenow (NIH Associate Director for AIDS Research and Director, Office of AIDS Research, United States)  
Charles Morrison (FHI 360, United States)

Oral  
13:00 - 14:30

Bristol

### OA13, Virus Control: Therapeutic Interventions

#### Chairs:

Mariano Esteban (Centro Nacional De Biotecnología, Spain)  
Moses Nsubuga (Stigmaless Uganda, Uganda)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Oral  
13:00 - 14:30

Oxford

### OA14, Antibody Functions Beyond Neutralization

#### Chairs:

Cynthia Derdeyn (Emory University, United States)  
Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)

Oral  
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

### OA15, New ARVs for Prevention

#### Chairs:

Juan Berenguer (Infectious Diseases at Hospital General Gregorio Marañón, Spain)  
Anton Pozniak (Chelsea and Westminster Hospital, United Kingdom)

Symposium  
15:00 - 16:30

Londres

### SY05, Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination

This session will review host responses to HIV/SIV infection within mucosal and lymphoid tissues in humans and nonhuman primates. Topics will include the role of molecular pathways implicated in natural immune control, early host response, novel mucosal innate lymphocyte subsets, and relevant findings from acute HIV infection studies.)

#### Chairs:

Guido Silvestri (Emory University, United States)  
Hendrik Streeck (Institute for HIV Research, Germany)

<b>Interfering with Interferons: How HIV Subverts the Interferon System to Facilitate Sexual HIV Transmission</b>	<b>15:00 - 15:22</b>
Anthony Cunningham (The Westmead Institute, The University of Sydney, Australia)	
<b>Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease</b>	<b>15:22 - 15:44</b>
Mary Carrington (Frederick National Laboratory for Cancer Research, United States)	
<b>HIV Persistence and the Immune Microenvironment in Lymph Nodes Following Initiation of cART During Hyperacute HIV-1 Infection</b>	<b>15:44 - 16:06</b>
Zaza Ndhlovu (University of KwaZulu Natal, South Africa)	
<b>The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface</b>	<b>16:06 - 16:28</b>
R. Keith Reeves (Beth Israel Harvard, United States)	

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Roundtable  
15:00 - 16:30

Bristol

### RT01, Accelerating Product Introduction for Impact

Millions of new HIV infections occur yearly despite availability of novel and effective HIV prevention products. This session will explore best practices for introduction of prevention products, and discuss successes and challenges using lessons learnt from completed demonstration projects. Best practices from sexual and reproductive health technologies and experiences from non-HIV vaccines will be used as examples of implementation planning for product introduction.

#### Chairs:

Nyaradzo Mgodzi (University of Zimbabwe Collaborative Research Program, Zimbabwe)  
Mitchell Warren (AVAC, United States)

<b>Preparing for Successful Implementation of Prevention Strategies</b> Hasina Subedar (Department of Health, South Africa)	<b>15:00 - 15:10</b>
<b>Learning From the Past: Planning for Future Success in Implementing Biomedical HIV Prevention Products</b> Alex Coutinho (Partners in Health, Rwanda)	<b>15:10 - 15:20</b>
<b>Successes and Shortcomings in Introducing Sexual and Reproductive Health Technologies: Insights From End-users, Providers and Policy Makers</b> Martha Brady (PATH, United States)	<b>15:20 - 15:30</b>
<b>Learning from History: Roll-out of Non-HIV Vaccines</b> Mark Feinberg (International AIDS Vaccine Initiative, United States)	<b>15:30 - 15:40</b>
<b>Introduction of New Health Technologies in HIV Prevention and Treatment Trials: Best Practices of Community Engagements and Communication in Peru</b> Maria del Rosario Leon (Impacta Salud y Educacion, Peru)	<b>15:40 - 15:50</b>
<b>Panel Discussion</b>	<b>15:50 - 16:30</b>

Symposium  
15:00 - 16:30

Oxford

### SY06, Let's Talk T Cells!

There is an urgent need to revisit approaches to elicit cell-mediated immunity for both vaccine prevention and cure strategies. The session will cover the latest and greatest candidates in pre-clinical and clinical development, as well as address the need to strike the right balance of T cell immunity.

#### Chairs:

Paul Goepfert (University of Alabama at Birmingham, United States)  
Julia G. Prado (AIDS Research Institute Irsicaixa, Spain)

<b>T Cell Responses in HIV-infected Children: Potential for Prevention or Cure?</b> Maximilian Muenchhoff (Pettenkofer-Institute, Germany)	<b>15:00 - 15:18</b>
<b>T Cells in Vaccine Trials</b> Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South Africa)	<b>15:18 - 15:36</b>

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

<b>What Defines an Effective T-cell Response to HIV?</b> Christian Brander (IrsiCaixa, Spain)	<b>15:36 - 15:54</b>
<b>Role of Tfh in Protective Immunity</b> Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)	<b>15:54 - 16:12</b>
<b>Vaccine-induced Th1-biased CD4 T Cell Responses: Too Much can be Bad</b> Rama Amara (Emory University, United States)	<b>16:12 - 16:30</b>

Symposium  
15:00 - 16:30

Marsella, Burdeos & Estrasburgo

### SY07, Optimizing PrEP Delivery for PrEP Users

This session will discuss the next phase of PrEP implementation – removing barriers to uptake and persistence of PrEP. The talks will focus on integrating PrEP with family planning. They will include: discussion of MPTs; discussion of new PrEP delivery strategies, such as pharmacy- or telemedicine-based delivery; exploration of “positive frame” methods of describing PrEP to help individuals determine whether they might benefit from PrEP; and discussion of new technologies for increasing uptake and persistence of PrEP.

#### Chairs:

Will Nutland (PrEPster, United Kingdom)  
Omar Sued (Fundacion Huesped, Argentina)

<b>Integrating PrEP and Reproductive Health Services and Preparing for MPT Delivery</b> Renee Heffron (University of Washington, United States)	<b>15:00 - 15:22</b>
<b>New Delivery Approaches: Improving PrEP Uptake and Persistence</b> Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)	<b>15:22 - 15:44</b>
<b>PrEP Messaging: Taking “Risk” Out of the Pitch</b> Sarit Golub (Hunter College, United States)	<b>15:44 - 16:06</b>
<b>Mobilizing Communities Through Innovations to Improve PrEP Uptake</b> Nittaya Phanuphak (Thai Red Cross AIDS Research Centre, Thailand)	<b>16:06 - 16:28</b>

Poster Discussion  
16:45 - 17:30

Londres

### PD06, Mechanisms of Natural Control

#### Chairs:

Yves Levy (INSERM, France)  
Marianne Mureithi (University of Nairobi, Kenya)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Poster Discussion  
16:45 - 17:30

Bristol

### **PD07, Beyond Acronyms: Understanding Young Women's Dreams, Realities and Perceptions**

**Chairs:**

Margaret McCluskey (USAID/GH/OHA/RES, United States)  
Definate Nhamo (Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe)

Poster Discussion  
16:45 - 17:30

Oxford

### **PD08, Trials and Tribulations in Roll Out**

**Chairs:**

Stacey Hannah (AVAC, United States)  
Morenike Ukpong (Institute of Public Health, Obafemi Awolowo University; New HIV Vaccine and Microbicide Advocacy Society, Nigeria)

**What Do Women Prefer in a Vaginal HIV Prevention Product? Findings From a Discrete Choice Experiment in Southern Africa** **16:54 - 17:03**

Erica Browne (RTI International, United States)

Poster Discussion  
16:45 - 17:30

Marsella, Burdeos & Estrasburgo

### **PD09, Long-acting Prevention Agents in Experimental Models**

**Chairs:**

Stephanie Barrett (Merck & Co., Inc., United States)

Poster Discussion  
16:45 - 17:30

Dresden & Stuttgart

### **PD10, Roadmaps for bNAb Elicitation**

**Chairs:**

Amelia Escolano (The Rockefeller University, United States)  
Ralf Wagner (University Of Regensburg, Germany)

Poster  
17:30 - 19:30

Poster Hall

### **Poster Session 02**

Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 23 October. Even-numbered abstracts will be presented in Poster Session 02 on Wednesday, 24 October.

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

**Thursday, 25 October 2018**

---

Oral  
08:30 - 10:00

Londres

### **OA16, Tickling the Germline**

**Chairs:**

Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)  
Ian Wilson (The Scripps Research Institute, United States)

Oral  
08:30 - 10:00

Bristol

### **OA17, Factors Influencing Viral Transmission and Spread**

**Chairs:**

Jason Brenchley (Niaid, United States)  
Nabila Seddiki (Inserm U955, Team 16, France)

Oral  
08:30 - 10:00

Oxford

### **OA18, Opinion 360: Meaningful Engagement From Research to Roll Out**

**Chairs:**

Manju Chatani-Gada (AVAC, United States)  
Kundai Chinyenze (International AIDS Vaccine Initiative, Kenya)

Oral  
08:30 - 10:00

Marsella, Burdeos & Estrasburgo

### **OA19, Stay With Me: Retention on PrEP**

**Chairs:**

Alex Carballo-Diéguez (Columbia University, HIV Center for Clinical and Behavioral Studies at New York State  
Psychiatric Institute and Columbia University, United States)  
Ferran Pujol Roca (Projecte dels NOMS-Hispanosida, Spain)

Oral  
10:30 - 12:00

Londres

### **OA20, Into the Future With Delivery Technologies**

**Chairs:**

Charles Lacey (University of York, United Kingdom)  
Zeda Rosenberg (IPM, United States)



HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## **Download Program (PDF)**

Oral  
10:30 - 12:00

Bristol

### **OA21, Linking Arms in Defense: Innate, Cellular and Humoral**

#### **Chairs:**

Francesca Chiodi (Karolinska Institutet, Sweden)  
Montserrat Plana (Institut d'Investigacions Biomèdiques August Pi i Sunyer, Spain)

Oral  
10:30 - 12:00

Oxford

### **OA22, Antibody Virus Tango**

#### **Chairs:**

Katie Doores (King's College London, United Kingdom)  
Feng Gao (Duke University, United States)

Oral  
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

### **OA23, Great Expectations: The Impact of PrEP**

#### **Chairs:**

Ume Abbas (Baylor College of Medicine, United States)  
Hong-Ha M. Truong (University of California, San Francisco, United States)

#### **Potential Impact of Increased ART and PrEP Coverage on the HIV Epidemic Among MSM in Atlanta: Mathematical Modelling for HPTN 078**

**11:45 - 12:00**

Kate M. Mitchell (Imperial College London, United Kingdom)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Meet the Experts Lunch  
12:00 - 13:00

Toulouse & Lyon

### ME03, Meet the Experts Lunch

#### Chairs:

John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)  
Connie Celum (University of Washington, United States)  
Guido Ferrari (Duke University Medical Center, United States)  
Genoveffa Franchini (National Cancer Institute, United States)  
Michael Gale (University of Washington, United States)  
Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)  
Diane Havlir (University of California at San Francisco, United States)  
Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute, South Africa)  
Sudhir Kasturi (Emory University, United States)  
Colleen Kelley (Emory University School of Medicine, United States)  
Maureen Luba (Centre for the Development of People (CEDEP), Malawi)  
John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States)  
Michael Meulbroek (BCN Checkpoint, Spain)  
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)  
Wanjiru Mukoma (LVCT Health, Kenya)  
Ram Prasad (Final Mile, United States)  
Robert H. Remien (NY State Psychiatric Institute and Columbia University, United States)  
Bruce Richman (U=U, United States)  
Lena Serghides (University Health Network and University of Toronto, Canada)  
Monica Vaccari (United States)  
Ariane van der Straten (RTI International, United States)  
Cara Wilson (University of Colorado, United States)

**Meet the Experts Lunch**

**12:00 - 13:00**

Symposium  
13:00 - 14:30

Londres

### SY08, Translating Vaccine Concepts to the Clinic: What We Need to Know

Based on current vaccine concepts, we will do a deep dive into immune mechanisms of protection. Using appropriate animal models, we will evaluate the crosstalk between adaptive and innate immunity, and signatures of protection. Finally, we will examine the role of susceptibility and how to modulate responses.

#### Chairs:

Nathalie Dereuddre-Bosquet (CEA, France)  
Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)

#### **Insights Into NK Cell Suppressor Activity in Secondary Lymphoid Organs Revealed by Animal Models**

**13:00 - 13:18**

Michaela Muller-Trutwin (Institut Pasteur, France)

#### **Influence of Vaccine Composition on Envelope Recognition by HIV-1 Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic Responses**

**13:18 - 13:36**

Guido Ferrari (Duke University Medical Center, United States)

#### **Antibody Interference and Durable Monocyte Innate Memory Decrease SIVmac251 Acquisition Risk Following Immunization with the DNA/ALVAC/gp120 Regimen**

**13:36 - 13:54**

Genoveffa Franchini (National Cancer Institute, United States)

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

<b>Protective Gene Expression Signature of the RhCMV/SIV Vaccine: Lessons for Human Studies</b>	<b>13:54 - 14:12</b>
Michael Gale (University of Washington, United States)	
<b>Modulating Durability of HIV-1 Env Specific Humoral Immunity With 3M-052, a TLR7/8 Targeted Adjuvant</b>	<b>14:12 - 14:30</b>
Sudhir Kasturi (Emory University, United States)	

Symposium  
13:00 - 14:30

Bristol

### **SY09, Choosing to Use: What People Want from HIV Prevention**

HIV prevention products currently in use were introduced after successful clinical trials for efficacy with little consideration of user preference. Results from completed efficacy trials consistently show evidence of low product use among adolescent and young women. This session will explore strategies for adherence support, risk perception, social marketing and end-user engagement strategies during product development.

#### **Chairs:**

Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)  
Andrew Mujugira (Infectious Diseases Institute, Uganda)

<b>Defining and Supporting Prevention Adherence</b>	<b>13:00 - 13:22</b>
Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)	
<b>Risk Perception and End-users' Perspective: Insights From Research of MPTs and HIV Prevention Products</b>	<b>13:22 - 13:44</b>
Ariane van der Straten (RTI International, United States)	
<b>Creating Demand for HIV Prevention Products, Programs and Services</b>	<b>13:44 - 14:06</b>
Wanjiru Mukoma (LVCT Health, Kenya)	
<b>Preference and Habits: How Do Users Decide and How Do We Find Out?</b>	<b>14:06 - 14:28</b>
Ram Prasad (Final Mile, United States)	

Symposium  
13:00 - 14:30

Oxford

### **SY10, Mucosal Environment: Barriers and Facilitators of Transmission**

This session will review how mucosal environments influence the likelihood that HIV transmission occurs following viral exposure. This includes a review of mucosal factors such as microbes and host responses that influence sexual transmission, and immunological mechanisms that dictate the integrity of the mucosal barrier and availability of HIV target cells.

#### **Chairs:**

William Kilembe (Zambia Emory HIV Research Project, Zambia)  
Lyle McKinnon (University of Manitoba, Canada)

<b>Microbiota and HIV Transmission</b>	<b>13:00 - 13:22</b>
Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute, South Africa)	

## Download Program (PDF)

<b>High Prevalence of Bacterial STIs in HIV-positive Persons: Transmission Implications &amp; Potential Interventions</b>	<b>13:22 - 13:44</b>
Connie Celum (University of Washington, United States)	
<b>The Rectal Mucosa in At-risk Men who Have Sex With Men: HIV Target Cells and the Inflammatory Response to Condomless Receptive Anal Intercourse</b>	<b>13:44 - 14:06</b>
Colleen Kelley (Emory University School of Medicine, United States)	
<b>How Do Different Components of the Mucosal Microenvironment Interact to Influence HIV Susceptibility?</b>	<b>14:06 - 14:28</b>
Cara Wilson (University of Colorado, United States)	

Roundtable  
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

## RT02, Getting to U: Undetectable = Untransmittable

People living with HIV who are durably virally suppressed are not able to transmit sexually. This roundtable will explore the psychological and behavioral components in deciding to start and stay on treatment, evaluate population impact of viral suppression, explore whether U=U holds for breastfeeding, describe what is known about clinical cohorts of persons being treated and their level of viral suppression, and discuss how to get the word out about U=U within communities.

### Chairs:

Judith Auerbach (University of California, San Francisco, United States)  
Ntando Yola (Desmond Tutu HIV Foundation, South Africa)

<b>Starting and Staying on ARVs</b>	<b>13:00 - 13:10</b>
Robert H. Remien (NY State Psychiatric Institute and Columbia University, United States)	
<b>What are the population level studies teaching us about U=U?</b>	<b>13:10 - 13:20</b>
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)	
<b>What Does U=U Mean for Breastfeeding?</b>	<b>13:20 - 13:30</b>
Lena Serghides (University Health Network and University of Toronto, Canada)	
<b>How Do You Know You're "U"?</b>	<b>13:30 - 13:40</b>
John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)	
<b>U=U: Unpacking the Message and the Movement</b>	<b>13:40 - 13:50</b>
Bruce Richman (U=U, United States)	
<b>Panel Discussion</b>	<b>13:50 - 14:30</b>

HIVR4P 2018,  
HIV Research for Prevention 2018,  
Madrid, Spain,  
21 - 25 October 2018

## Download Program (PDF)

Closing Plenary  
15:00 - 16:30

Auditorium

### PL04, Putting It Together: Strategies to End the Epidemic

Plenary 4 looks ahead to the potential impact of implementing multiple prevention strategies, and challenges researchers and advocates from every community and prevention field to pool our knowledge, share our experiences and move forward together to help end the epidemic.

#### Chairs:

Jose Alcamí (Instituto de Salud Carlos III, Spain)  
Susan Buchbinder (San Francisco Department of Public Health, United States)  
Mike Chirenje (University of Zimbabwe, Zimbabwe)  
Georgia Tomaras (Duke University, United States)

<b>Combination prevention: What will it take to make it work?</b>	<b>15:00 - 15:20</b>
Diane Havlir (University of California at San Francisco, United States)	
<b>Implementing a Multi-disciplinary Prevention Revolution</b>	<b>15:20 - 15:35</b>
Maureen Luba (Centre for the Development of People (CEDEP), Malawi)	
<b>The Impact of Prevention Strategies on HIV Incidence in a Community Center</b>	<b>15:35 - 15:50</b>
Michael Meulbroek (BCN Checkpoint, Spain)	
<b>A Path Forward for HIV Vaccines</b>	<b>15:50 - 16:10</b>
John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States)	
<b>Panel Discussion with Closing Plenary Speakers</b>	<b>16:10 - 16:25</b>
<b>Closing Remarks and Handover to 2020</b>	<b>16:25 - 16:30</b>
Susan Buchbinder (San Francisco Department of Public Health, United States)	